COVID-19 appears to be associated with a disproportionate risk of thrombosis.
The occurrence of thrombosis is a frequent complication of many medical and
surgical conditions. Their prevention by LMWH is the option of choice as well
as their early diagnosis in this pandemic context. In addition, several recent observations support that severe pulmonary
embolism is very common in hospitalized patients with COVID-19. We report the
case of late pulmonary embolism in a 26-year-old patient with a medical history
of (SARS-CoV2) and newly discovered diabetes. The clinical examination
found exertional dyspnea, intense chest pain, blood pressure at 145/85mmHg,
heart rate at 129 bpm, respiratory rate at 25 cycles/min, blood sugar at 1.45
g/l, oxygen saturation at 92%. In front of this clinical picture, the thoracic
CT angiography to ask shows a pulmonary embolism of the right segmental and
sub-segmental branches less marked on the left, involving the lingular and
basal branches; the
management was limited to anticoagulation associated with rehabilitation
sessions (respiratory physiotherapy).
References
[1]
Walls, A.C., Park, Y.-J., Tortorici, M.A., Wall, A., McGuire, A.T. and Veesler, D. (2020) Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 181, 281-292.e6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102599 https://doi.org/10.1016/j.cell.2020.02.058
[2]
Zhang, H., Penninger, J.M., Li, Y., Zhong, N. and Slutsky, A.S. (2020) Angiotensin-Converting Enzyme 2 (ACE2) as a SARS-CoV-2 Receptor: Molecular Mechanisms and Potential Therapeutic Target. Intensive Care Medicine, 46, 586-590. https://doi.org/10.1007/s00134-020-05985-9
[3]
Thachil, J., Tang, N., Gando, S., et al. (2020) ISTH Interim Guidance on Recognition and Management of Coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis, 18, 1023-1026. https://doi.org/10.1111/jth.14810
[4]
Marietta, M., Ageno, W., Artoni, A., et al. (2020) COVID-19 and Haemostasis: A Position Paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus, 18, 167-169.
[5]
GFHT/GIHP (2020) Proposition pour le traitement anticoagulant pour la prévention du risque thrombotique chez un patient hospitalisé avec COVID-19. https://site.geht.org/docutheque
[6]
Patell, R., Bogue, T., Koshy, A.G., Bindal, P., Merrill, M., Aird, W.C., et al. (2020) Post-Discharge Thrombosis and Hemorrhage in Patients with COVID-19. Blood, 136, 1342-1346. https://doi.org/10.1182/blood.2020007938
[7]
Zuily, S., Dufrost, V. and Wahl, D. (2020) Thrombose artérielle et veineuse au cours du COVID-19. Archives des Maladies du Coeur et des Vaisseaux—Pratique, 2020, 16-19. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413116 https://doi.org/10.1016/j.amcp.2020.08.003
[8]
Fogarty, H., Townsend, L., Ni, C.C., Bergin, C., Martin-Loeches, I., Browne, P., et al. (2020) COVID-19 Coagulopathy in Caucasian Patients. British Journal of Haematology, 189, 1044-1049. https://doi.org/10.1111/bjh.16791
[9]
Levi, M., Thachil, J., Iba, T. and Levy, J.H. (2020) Coagulation Abnormalities and Thrombosis in Patients with COVID-19. The Lancet Haematology, 7, E438-E440.
[10]
Leisman, D.E., Deutschman, C.S. and Legrand, M. (2020) Facing COVID-19 in the ICU: Vascular Dysfunction, Thrombosis, and Dysregulated Inflammation. Intensive Care Medicine, 46, 1105-1108. https://doi.org/10.1007/s00134-020-06059-6
[11]
Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S. and Manson, J.J. (2020) COVID-19: Consider Cytokine Storm Syndromes and Immuno-Suppression. The Lancet, 395, 1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
[12]
Varga, Z., Flammer, A.J., Steiger, P., Haberecker, M., Ander-Matt, R., Zinkernagel, A.S., et al. (2020) Endothelial Cell Infection and Endotheliitis in COVID-19. The Lancet, 395, 1417-1418. https://doi.org/10.1016/S0140-6736(20)30937-5
[13]
Helms, J., Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Merdji, H., et al. (2020) High Risk of Thrombosis in Patients in Severe SARS-CoV-2 Infection: A Multicenter Prospective Cohort Study. Intensive Care Medicine, 46, 1089-1098. https://doi.org/10.1007/s00134-020-06062-x
[14]
Yan, S.F., Mackman, N., Kisiel, W., Stern, D.M. and Pinsky, D.J. (1999) Hypoxia/Hypoxemia-Induced Activation of the Procoagulant Pathways and the Pathogenesis of Ischemia-Associated Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 19, 2029-2035. https://doi.org/10.1161/01.ATV.19.9.2029
[15]
Gupta, N., Zhao, Y.-Y. and Evans, C.E. (2019) The Stimulation of Thrombosis by Hypoxia. Thrombosis Research, 181, 77-83. https://doi.org/10.1016/j.thromres.2019.07.013
[16]
Tignanelli, C.J., et al. (2020) Antihypertensive Drugs and Risk of COVID-19? The Lancet Respiratory Medicine, 8, e30-e31. http://www.thelancet.Com/respiratory
[17]
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. (2020) Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. The Lancet (London, England), 395, 507-513. https://doi.org/10.1016/S0140-6736(20)30211-7
[18]
Tang, N., Li, D., Wang, X. and Sun, Z. (2020) Abnormal Coagulation Parameters Are Associated with Poor Prognosis in Patients with Novel Coronavirus Pneumonia. Journal of Thrombosis and Haemostasis, 18, 844-847. https://doi.org/10.1111/jth.14768
[19]
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., et al. (2020) Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. The Lancet (London, England), 395, 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3
[20]
Amin, A.N., Varker, H., Princic, N., Lin, J., Thompson, S. and Johnston, S. (2012) Duration of Venous Thromboembolism Risk across a Continuum in Medically Ill Hospitalized Patients. Journal of Hospital Medicine, 7, 231-238. https://doi.org/10.1002/jhm.1002
[21]
Samama, M.M., Cohen, A.T., Darmon, J.Y., Desjardins, L., Eldor, A., Janbon, C., et al. (1999) A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. New England Journal of Medicine, 341, 793-800. https://doi.org/10.1056/NEJM199909093411103
[22]
Kearon, C., Akl, E.A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., et al. (2016) Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest, 149, 315-352. https://doi.org/10.1016/j.chest.2015.11.026
[23]
Hull, R.D., Schellong, S.M., Tapson, V.F., Monreal, M., Samama, M.-M., Nicol, P., et al. (2010) Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients with Recently Reduced Mobility: A Randomized Trial. Annals of Internal Medicine, 153, 8-18. https://doi.org/10.7326/0003-4819-153-1-201007060-00004
[24]
Cohen, A.T., Spiro, T.E., Büller, H.R., Haskell, L., Hu, D., Hull, R., et al. (2013) Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. New England Journal of Medicine, 368, 513-523. https://doi.org/10.1056/NEJMoa1111096
